Key opinion leaders and presenters at the 2022 American Academy of Neurology annual meeting share their perspectives on the latest advances in the management of patients with multiple sclerosis.
EP. 1: The DeepGRAI Registry in Multiple Sclerosis
Robert Zivadinov, MD, PhD, offers his insight into the findings from the DeepGRAI registry of thalamic volume measurement on multicenter clinical-quality T2-FLAIR images in multiple sclerosis.
EP. 2: Ofatumumab Safety Data and Novel Approaches to MS
Stephen Krieger, MD, spoke about the latest safety data on ofatumumab (Kesimpta; Novartis) and the progress made in novel therapeutics for multiple sclerosis.
EP. 3: No Evidence of Disease Activity in MS With Ozanimod
Ludwig Kappos, MD, FEAN, FAAN, provided insight on a new analysis that showed greater proportions of patients achieving no evidence of disease activity on ozanimod compared with interferon ß-1a.
EP. 4: BTK Inhibitors and Novel Approaches to Multiple Sclerosis
Robert K. Shin, MD, offered his perspective on the novel therapies being developed for multiple sclerosis, highlighting the potential of Bruton tyrosine kinase inhibitors for progressive disease.
EP. 5: Multiple Sclerosis Disability Improvements With Ublituximab
Bruce Cree, MD, PhD, MAS, FAAN, shared his thoughts on the data from the ULTIMATE I and II studies of ublituximab's effect on measures of MS disability, including EDSS and 9HPT scores.
EP. 6: NOVA Study Data on Natalizumab Dosing Strategies
Stephen Krieger, MD, spoke about the phase 3b NOVA study (NCT03689972) data presented at AAN 2022 on natalizumab (Tysabri; Biogen) dosing regimens.
EP. 7: Progress in MS Therapeutic Development and Shifts in the Landscape
Discussing the progress made in therapeutic approaches to multiple sclerosis, Robert K. Shin, MD, shared his perspective on how the focus on treatments has shifted in the community.
EP. 8: Comparing Reactive Microglia and Astrocytes in Secondary Progressive Multiple Sclerosis
Robert Zivadinov, MD, PhD, discusses the design of a novel comparative study assessing the effect of siponimod (Mayzent; Novartis) and ocrelizumab (Ocrevus; Genentech) on microglia and astrocytes in patients with SPMS.
2 Commerce Drive Cranbury, NJ 08512